MLKL and neoplasm: In pancreatic ductal adenocarcinoma (PDAC), MLKL has been observed to enhance CD47-SIRPα signaling in tumor cells, which in turn inhibits macrophage phagocytosis and enables tumor cells to evade immune clearance.